Postdoctoral Researcher for the Incalab

REF: 25-172_R_FR

About the research group

The Infections and Cancer Laboratory (INCALAB) focuses on cancers linked to infections, particularly human papillomavirus (HPV). INCALAB develops molecular tools to improve prevention, diagnosis, and treatment, conducts basic and pre-clinical research on HPV natural history and molecular markers, and collaborates with diagnostic companies to evaluate new molecular assays. The lab also provides technical support to UNIC EMG and UNIC II projects and serves as a reference lab for cervical cancer screening in Catalonia.

About the role

The post-doctoral researcher will join the group’s research line, whose main objective is to determine whether prophylactic vaccination in HPV-positive individuals could reduce infectivity in different mucosal sites and thereby limit the potential transmission of the virus to others.Within this line of research, the postdoctoral researcher will be responsible for developing various molecular assays to determine the presence of HR-HPV types, neutralizing antibodies, and the infectivity of cervical, anal, oral, and urine samples collected in two ongoing clinical trials—RIFT-BCN and RIFT-SSA—currently underway and led by the group.

Job requirements

Professional experience

· Experience in the analysis of biological samples for the detection of HPV and associated biomarkers.
· Experience working with clinical cohorts, including sample handling, processing, and documentation under standardized protocols.
· Experience in scientific communication, including presentations at conferences, seminars, or internal research meetings.

Education and training

· Ph.D. in infections Diseases or similar
· Masters Degree in Infectious Diseases and Public Health.
· Bachelors Degree in Life Sciences (BSc), Biochemistry or similar 

Technical & soft skills

· Knowledge in database management.
· Previous experience in the detection of pathogenic organisms.
· Experience in the development of new molecular assays, including PCR-based detection methods and immunoassays.
· Authorship of publications in indexed journals within the proposed research area
· Ability to manage multiple research tasks simultaneously, meeting deadlines in the context of clinical trial timelines.

Languages

· Good command of the English language.

We will value, but not required

· Very proactive and decisive person, high organizational ability.

What do we offer

· No. of positions: 1

· Estimated start date: 20/01/2026

· Contract duration: Permanent by Project

· Estimated annual gross salary: The salary will be in accordance with IDIBELL's salary scales and the experience provided.

· You will be part of a multicultural team. We have a fun loving and friendly international work environment.

· Flexible working schedule - We know you have a life outside of work and we will work with you to make sure it's kept that way.

· Possibility to work some days in remote -Teleworking

· 26 working days of holiday per year

· System of accumulated hours for employees, from 88 to 104 hours depending on the year (11 to 13 working days), to attend to personal matters.

· Paid leave package

· Benefits of constant training are offered

· We offer and promote diverse and inclusive conditions. Applicants are made free from any discrimination. Specifically IDIBELL works to improve gender equality in all areas with the aim of achieving gender balance, but maintaining the most scrupulous respect to any choice at the level of gender identity. Please express yourself freely, safely and non-binarily, if that's the case.

Deadline: Please submit your application by  16/12/2025

Data protection notice

In compliance with the obligations established in the General Regulation of Data Protection (RGPD), which is the Regulation (EU) 2016/679 of the Parliament and of the Council, of April 27, 2016, and the Organic Law 3/2018, of December 5, Protection of Personal Data and guarantee of digital rights, it is reported that the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), CIF G58863317, with address Av. Granvia de l'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, will process your personal data, as the controller, to apply for the position, maintain communication concerning the status of the candidature, to access the delivered CV; to compare that your data is in accordance with the offers announced by IDIBELL and to verify, where appropriate, that the information provided is accurate. You can find more information in our Privacy Policy at https://idibell.cat/en/privacy-policy-2/, request more information about the data processing carried out and exercise your rights of access, rectification, deletion, opposition, portability, limitation of processing by sending a request at email: dataprotection@idibell.cat. If you consider that you have not obtained satisfaction in exercising your rights, you may submit a claim to Catalan Data Protection Authority.

Our institute

IDIBELL is a research center that integrates the biomedical research of the Bellvitge University Hospital (HUB), the Catalan Institute of Oncology (ICO), and the University of Barcelona in the Bellvitge Campus (UB), and the Viladecans Hospital (HV). The research focuses of IDIBELL are cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the pivots on which researchers work every day in order to improve the quality of life of citizens.

Observations:

The 'HR Excellence in Research' award represents IDIBELL’s commitment to the implementation of Human Resources policies, which oversee the attracting and development of talent in an open, transparent, and based on personal merit, in alignment with the principles of the European Charter for Researchers and the Code of Conduct for the Recruitment Researchers (Charter and Code).

IDIBELL is committed to the principles of the Code of Conduct for the Recruitment of Researchers of the European Commission and the implementation of open, transparent and merit-based recruitment (OTMR).

The project leading to this labour contract has received funding by Bill&Melinda Gates Foundation. We thank CERCA Programme /Generalitat de Catalunya for institutional support.